Integra LifeSciences Holdings Co. (NASDAQ:IART) Short Interest Up 24.9% in April

Integra LifeSciences Holdings Co. (NASDAQ:IART) saw a large growth in short interest in April. As of April 15th, there was short interest totalling 2,610,000 shares, a growth of 24.9% from the March 31st total of 2,090,000 shares. Approximately 4.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 725,500 shares, the days-to-cover ratio is presently 3.6 days.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on IART shares. JMP Securities dropped their target price on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a research report on Thursday, February 29th. Truist Financial decreased their price target on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a report on Friday, March 1st. Citigroup raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price target on the stock in a report on Wednesday, April 3rd. Finally, StockNews.com lowered shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Friday, April 5th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $44.89.

Integra LifeSciences Stock Down 0.2 %

Shares of Integra LifeSciences stock traded down $0.07 during trading on Tuesday, reaching $29.17. 650,226 shares of the company traded hands, compared to its average volume of 702,239. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.45 and a quick ratio of 2.18. Integra LifeSciences has a 1-year low of $27.18 and a 1-year high of $56.21. The company has a 50 day moving average price of $35.02 and a 200-day moving average price of $38.71. The firm has a market capitalization of $2.29 billion, a PE ratio of 35.14, a P/E/G ratio of 0.85 and a beta of 1.12.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The company had revenue of $397.00 million for the quarter, compared to analyst estimates of $399.30 million. During the same quarter in the previous year, the firm earned $0.94 EPS. The firm’s revenue was down .3% on a year-over-year basis. As a group, equities research analysts expect that Integra LifeSciences will post 3.19 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of IART. Oak Thistle LLC raised its holdings in Integra LifeSciences by 115.0% during the third quarter. Oak Thistle LLC now owns 13,424 shares of the life sciences company’s stock worth $513,000 after buying an additional 7,181 shares during the last quarter. Ellsworth Advisors LLC bought a new stake in shares of Integra LifeSciences in the 3rd quarter worth $3,883,000. Raymond James & Associates grew its stake in shares of Integra LifeSciences by 28.7% in the 3rd quarter. Raymond James & Associates now owns 204,325 shares of the life sciences company’s stock worth $7,803,000 after acquiring an additional 45,554 shares in the last quarter. Strs Ohio grew its stake in shares of Integra LifeSciences by 6.9% in the 3rd quarter. Strs Ohio now owns 41,730 shares of the life sciences company’s stock worth $1,593,000 after acquiring an additional 2,679 shares in the last quarter. Finally, Advisor Partners II LLC bought a new stake in shares of Integra LifeSciences in the 3rd quarter worth $241,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.